ArticlemBio2026
A Val292 substitution combined with an alanine duplication (ADUP) in the Ω loop of ADC β-lactamase confers reduced susceptibility to advanced β-lactam agents, including cefiderocol.
Akito Kawai, Christi L McElheny, Ryan K Shields, Cesar A Arias, David L Paterson, Robin Patel, Robert A Bonomo, Vance G Fowler, David van Duin, Yohei Doi
Abstract read
In one paragraphArticle in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Akito Kawai *Department of Microbiology, Fujita Health University School of Medicine, Toyoake, Japan.ORCID 0000-0001-5695-8814 Christi L McElheny *Center for Innovative Antimicrobial Therapy, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Ryan K ShieldsCenter for Innovative Antimicrobial Therapy, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-9794-5665 David L PatersonADVANCE-ID, Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
Robin PatelDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology and Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-6344-4141 Robert A BonomoCase Western Reserve University University-Veteran Affairs Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Research and Medical Services, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.ORCID 0000-0002-3299-894X Vance G FowlerDuke Clinical Research Institute, Duke University, Durham, North Carolina, USA.
David van DuinDivision of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0003-4784-3227 Funding
Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8MMechanisms of cefiderocol resistanceR21AI151362 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DOI, YOHEI · 2020 to 2021
$420kNIH HHS R21AI151362NIH HHS UM1AI104681
6 · The paper itselfAbstract
Indexed as
Acinetobacter baumanniiAnti-Bacterial Agentsbeta-Lactamasesbeta-LactamsCephalosporinaseCephalosporinsAcinetobacter InfectionsAmino Acid SubstitutionBacterial Proteinsbeta-Lactam ResistanceCefiderocolHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsBacterial Proteinsbeta-Lactamasesbeta-LactamsCefiderocolCephalosporinaseCephalosporinsADC-227ADC-33 variantbeta-lactamasecarbapenem-resistant Acinetobacter baumanniicefiderocol
Identifiers
PMID41949313
PMCPMC13170308
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390